Sumitomo Pharma America unveils promising new leukemia and myelofibrosis data ahead of ASH 2025
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
The antibody was designed and developed at Abzena’s Cambridge, UK,
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Subscribe To Our Newsletter & Stay Updated